Oncology

Effective management of immune checkpoint inhibitor-related toxicities requires early intervention, evolving guideline adherence, and multidisciplinary collaboration, with steroids remaining a key treatment.

The antibody-drug conjugate is currently undergoing evaluation in a phase 1 trial that enrolled patients with pancreatic cancer and squamous non-small cell lung cancer (NSCLC).

The results should lead to a guideline update recommending extended treatment with a reduced-dose anticoagulant in this patient population.

PD-L1 immune checkpoint inhibitors are now standard for early-stage non-metastatic non-small cell lung cancer (NSCLC), with neoadjuvant, adjuvant, and perioperative strategies improving survival and outcomes.

Approval of durvalumab is in combination with gemcitabine and cisplatin as neoadjuvant treatment for adults with muscle invasive bladder cancer.

Aromatase inhibitors were superior to tamoxifen in reducing risk of contralateral breast cancer.

Patients with chronic lymphocytic leukemia (CLL) show weakened T-cell memory responses to COVID-19 vaccination.

The findings provide a deeper understanding of the mechanisms underlying breast cancer progression and treatment resistance.

Patients achieved statistically significant benefits in progression-free survival and overall response rates.

Megan May, PharmD, BCOP, FHOPA, FAPO, discusses lurbinectedin and tarlatamab and what ongoing research in the small cell lung cancer (SCLC) space entails.

National Adverse Drug Event Awareness Day was established to promote awareness, drive policy changes, and encourage health care professionals and patients to prioritize medication safety.

Specialty distribution models, including limited drug distribution systems, ensure safe medication access but can create barriers for patients, making medically integrated pharmacies essential in coordinating care.

After decades without improvements, an expert with Baptist Health described the small cell lung cancer (SCLC) space as “exciting” following multiple innovations in the past few years.

BeeR is a bacterial protein from the family Verrucomicrobiota that influences cell shape and division.

The combination was approved for treatment of patients with gastroesophageal junction (GEJ) adenocarcinoma.

The findings extend prior data underscoring the clinical benefit of the agent and its place in global clinical practice guidelines.

Sharita Howe, PharmD, discusses her recent acknowledgement by MM+M, who acknowledged her as a part of the next wave of health care leaders in their recognition of 40 under 40 leaders in health care.

David S. Bateshansky, PharmD, BCOP, discusses his role as an oncology pharmacist at USC Norris Comprehensive Cancer Center, noting the evolving recognition of pharmacists' contributions on cancer care teams.

Tarlatamab was approved by the FDA in May 2024 for patients who progressed after platinum-based chemotherapy.

The Western diet was associated with increased risk of lung cancer.

Approximately 10% of patients with multiple myeloma have pathogenic germline variants, indicating a hereditary risk.

Vepdegestrant is an experimental oral PROteolysis TArgeting Chimera that degrades estrogen receptor (ER) in patients with metastatic breast cancer.

Wafa Samara, PharmD, vice president and chief pharmacy officer at City of Hope, highlights the vital role of oncology pharmacists at City of Hope in improving patient outcomes, conducting and leading research, and working as integral members of the multidisciplinary care team.

Even when safe, oral supplement use may not be appropriate to use during cancer treatment or recovery.

Conference Co-Chair and American Association for Cancer Research (AACR) Past President Elaine R. Mardis, PhD, explains that the conference provides pharmacy professionals with insights into the application of large-scale cancer genomics studies to real-world therapeutic responses.

Amir Ali, PharmD, BCOP, discusses his experience as an oncology pharmacist in both direct and indirect patient care at the University of Southern California (USC) Norris Comprehensive Cancer Center.

Pharmacists also navigate the REMS program and monitor and manage adverse effect profiles associated with bispecifics.

The novel formulation of trametinib has the potential to change the treatment paradigm of human papillomavirus (HPV) and prevent infections before they progress to deadly cancers.

The cancers linked with per- and polyfluoroalkyl substance (PFAS) exposure included nonastrocytoma gliomas, acute myeloid leukemia, and Wilms tumors.

A pilot program integrated oncology pharmacists into prior authorization workflows to streamline and expedite medication approvals.